Want to see SGMOQ full AI Analyst Report?

Sangamo Therapeutics (SGMOQ) Price & Analysis

2,692 Followers

SGMOQ Stock Chart & Stats

$0.06

>-$0.01(-10.96%)

At close: Jul 24 4:00 PM EDT

$0.06

>-$0.01(-10.96%)

Day’s Range― - ―

52-Week Range$0.03 - $0.77

Previous CloseN/A

Volume4.35M

Average Volume (3M)7.65M

Market Cap

$60.07M

Enterprise Value$87.94

Total Cash (Recent Filing)$27.59M

Total Debt (Recent Filing)$19.33M

Price to Earnings (P/E)―

Beta2.34

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding414,288,850

10 Day Avg. Volume4,237,466

30 Day Avg. Volume7,646,780

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)-8.25

Price to Sales (P/S)2.98

P/FCF Ratio-1.21

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$2.00

Price Target Upside3233.33% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)-0.3

Revenue Forecast (FY)$9.90M

Bulls Say, Bears Say

Bulls Say

Regulatory Clarity And BLA ProgressFDA agreement on an accelerated approval endpoint and a rolling BLA that is materially advanced reduces regulatory uncertainty for ST‑920. This durable regulatory clarity shortens potential approval path, strengthens the program's de‑risking profile and improves the prospect of partner interest if funding is secured.

Durable Clinical Efficacy SignalsLong‑term follow‑up showing sustained biomarker response and many patients off enzyme replacement suggests single‑dose durability. Durable clinical benefit supports long‑term value, payer acceptance, and commercial differentiation versus chronic therapies, underpinning the program's strategic attractiveness.

Platform Breadth And Scientific VisibilityDemonstrated platform advances (zinc‑finger regulation, MINT integration) and visibility at major conferences indicate scalable core technology. A versatile platform enables multiple programs and partnership/licensing opportunities, spreading technical risk and offering structural upside beyond any single asset.

Bears Say

Chapter 11 And Asset Sale ProcessActive Chapter 11 proceedings and an approved auction process create existential risk for equity and can force asset sales or reorganization. This structural event can terminate or materially change R&D programs, impair long‑term continuity, and shift priority toward creditor outcomes over scientific execution.

Persistent Heavy Cash Burn And Weakened Balance SheetSustained negative operating and free cash flow combined with negative equity sharply limit financial flexibility. Over months this forces dilutive financings, asset sales, or partnerships on unfavorable terms, constraining the company's ability to fund pivotal regulatory filings and long‑lead clinical programs independently.

Delisting, Liquidity Loss And Funding UncertaintyNasdaq delisting and OTC transition reduce institutional access and liquidity, making large partner deals or equity raises harder. Coupled with management's explicit funding and going‑concern caveats, this structurally raises execution risk and lengthens timelines for regulatory completion or commercialization.

Sangamo Therapeutics News

Sangamo Concludes Section 363 Asset Sales in Bankruptcy

Sangamo Therapeutics ( ($SGMOQ) ) has issued an update. On August 13, 2026, Sangamo Therapeutics, which filed for...

15h ago

Sangamo Therapeutics Reports Post-Bankruptcy Operating Developments

Sangamo Therapeutics ( ($SGMOQ) ) has shared an announcement. As of June 23, 2026, Sangamo Therapeutics filed for...

1d ago

SGMO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Sangamo Biosciences (SGMO) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street analysts...

5d ago

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

Sangamo Therapeutics ( ($SGMOQ) ) just unveiled an announcement. Sangamo Therapeutics, Inc. filed for Chapter 11 bankruptcy protection...

24d ago

SGMOQ FAQ

What was Sangamo Therapeutics’s price range in the past 12 months?

Sangamo Therapeutics lowest stock price was $0.03 and its highest was $0.77 in the past 12 months.

What is Sangamo Therapeutics’s market cap?

Sangamo Therapeutics’s market cap is $60.07M.

When is Sangamo Therapeutics’s upcoming earnings report date?

Sangamo Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 76 days.

How were Sangamo Therapeutics’s earnings last quarter?

Currently, no data Available

Is Sangamo Therapeutics overvalued?

According to Wall Street analysts Sangamo Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sangamo Therapeutics pay dividends?

Sangamo Therapeutics does not currently pay dividends.

What is Sangamo Therapeutics’s EPS estimate?

Sangamo Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sangamo Therapeutics have?

Sangamo Therapeutics has 414,288,850 shares outstanding.

What happened to Sangamo Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sangamo Therapeutics?

Currently, no hedge funds are holding shares in SGMOQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sangamo Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-30.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sangamo Therapeutics

Sangamo Therapeutics (SGMO) is a clinical-stage biotechnology company focused on developing genomic medicine therapies. The company’s work centers on gene regulation and gene editing approaches, including zinc finger protein (ZFP) technology, to create potential treatments for serious genetic diseases and other conditions. Sangamo’s activities primarily span research and development, clinical advancement of its pipeline, and partnering its platform technologies with other biopharmaceutical companies.

Sangamo Therapeutics (SGMOQ) Earnings & Revenues

Historic Earnings Reports

SGMOQ Company Deck

SGMOQ Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.View all SGMOQ earnings summaries

SGMOQ Stock 12 Month Forecast

Average Price Target

$2.00

▲(3233.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.561,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.539,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.674,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.598,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.425,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.567,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.429,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.211,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.057,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.073,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >